GTS Securities’s Myriad Genetics MYGN Stock Holding History

GTS Securities’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-11,779	Closed	-$189K	–	4285
2023 Q3	$189K	Buy	+11,779	New	+$224K	﹤0.01%	3434

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GTS Securities's MYGN Position: Q4 2023 in Review

GTS Securities sold out of Myriad Genetics (MYGN) in Q4 2023, closing a stake of 11,779 shares — an estimated $189K sold.

GTS Securities first reported a position in MYGN in Q3 2023 and held it in 1 quarter. The position peaked at $189K in Q3 2023. 194 funds tracked by Wall St. Rank hold MYGN as of Q4 2023.

GTS Securities reported no remaining Myriad Genetics position as of Q4 2023 after selling out during the quarter.
GTS Securities sold 11,779 Myriad Genetics shares in Q4 2023, an estimated $189K.
GTS Securities first reported a position in Myriad Genetics in Q3 2023 and held it in 1 quarter.
GTS Securities's Myriad Genetics position peaked at $189K in Q3 2023.
194 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2023.

Based on GTS Securities's 13F filing for Q4 2023, filed 15 Feb 2024.